Zinc Carnosine (PepZin GI): Gastric Mucosal Protection, H. pylori Adjunct & Gut Lining Support

What is zinc carnosine?

Zinc carnosine (zinc L-carnosine, Polaprezinc, Z-103, PepZin GI) is a chelate formed by the coordination of one zinc ion with two molecules of L-carnosine (beta-alanyl-L-histidine). Unlike typical zinc supplements where zinc is loosely associated with an anion (gluconate, picolinate, acetate) and rapidly dissociates in stomach acid, zinc carnosine forms a polymeric, cross-linked complex that is highly stable at gastric pH.

The compound was developed by Hamari Chemicals Ltd. in Japan and approved as a prescription drug (Polaprezinc) by the Japanese Ministry of Health in 1994 for the treatment of gastric ulcers. Japan has a long tradition of researching zinc and carnosine in gastrointestinal contexts, and the resulting evidence base — while primarily Japanese-origin — is relatively robust compared to most supplement categories.

In global supplement markets, zinc carnosine is sold under the PepZin GI trade name, licensed from Hamari, and has been incorporated into gut health formulas by many supplement manufacturers. The same chemistry as the prescription drug — the intact zinc-carnosine chelate — is what gives it its clinical properties.

How zinc carnosine protects the gastric mucosa

The mechanism of action has three complementary components:

1. Chelate stability and selective adhesion: In the acidic, protein-rich environment of the stomach, the zinc-carnosine polymer remains intact rather than dissociating. It selectively adheres to ulcerated or inflamed gastric mucosal tissue — possibly via electrostatic interaction with damaged epithelium — concentrating its activity at the sites of injury rather than releasing uniformly into the gastric lumen.
2. Sustained local zinc release: Once adherent to the mucosa, the chelate slowly releases zinc ions locally. Zinc is a cofactor for matrix metalloproteinases and is required for the proliferation and migration of gastric epithelial cells during mucosal repair. It also has direct antimicrobial properties that may inhibit H. pylori locally.
3. Carnosine's antioxidant and anti-inflammatory effects: L-carnosine is a histidine-containing dipeptide with antioxidant, metal-chelating, and anti-inflammatory properties. In the gastric epithelium, carnosine quenches reactive oxygen species generated by H. pylori-induced inflammation and reduces IL-8 secretion by gastric epithelial cells.

This combination of targeted delivery, mucosal adhesion, zinc-mediated repair, and carnosine's antioxidant activity is why the intact chelate is more effective than free zinc or free carnosine administered separately in animal models.

Evidence-based benefits of zinc carnosine

1. Gastric ulcer healing and mucosal protection — moderate evidence

Japanese clinical trials conducted during the regulatory review process for Polaprezinc established efficacy for peptic ulcer healing. A multicenter, double-blind trial comparing polaprezinc to cimetidine (an H2 blocker) found equivalent ulcer healing rates at 8 weeks (approximately 60–70% complete healing in both groups), with better tolerability in the polaprezinc group. A subsequent trial vs. plebo in patients with endoscopically confirmed gastric ulcers showed significantly faster mucosal healing with polaprezinc at the 150 mg/day dose (75 mg BID). These are regulatory-quality trials conducted to Japanese standards; they form the core of the evidence base.

2. H. pylori eradication adjunct — moderate evidence

Several Japanese RCTs have tested zinc carnosine as an add-on to standard triple therapy (proton pump inhibitor + two antibiotics) for H. pylori eradication. The rationale: zinc inhibits H. pylori urease (an enzyme critical to H. pylori survival in the stomach) and reduces gastric inflammation during antibiotic treatment, potentially improving eradication success rates and reducing treatment-associated mucosal damage. A 2007 RCT by Suzuki et al. (n=142) found that adding polaprezinc to triple therapy improved eradication rates and reduced post-treatment mucosal damage compared to triple therapy alone. These findings are consistent across several smaller studies, though all are Japanese-origin.

3. NSAID-induced gastric mucosal damage — moderate evidence

NSAIDs (aspirin, ibuprofen, naproxen, indomethacin) cause gastric mucosal damage by inhibiting COX-1-mediated prostaglandin synthesis, which normally maintains gastric epithelial barrier function. Animal models consistently show that zinc carnosine pre-treatment substantially reduces NSAID-induced mucosal erosion. A small human trial (Kashimura et al.) demonstrated that zinc carnosine significantly attenuated gastric mucosal injury in volunteers receiving indomethacin compared to placebo, as measured by endoscopy. This is a clinically useful niche: people who must take NSAIDs regularly and cannot take PPIs, or who want to minimize PPI use alongside NSAIDs.

4. Exercise-induced gut permeability — emerging evidence

Intense endurance exercise increases intestinal permeability (sometimes called "leaky gut") via a mechanism involving heat stress on enterocytes and splanchnic blood flow reduction. A 2014 Australian RCT by Pugh et al. (n=10 cyclists) found that zinc carnosine supplementation for 14 days before an endurance exercise challenge significantly blunted the post-exercise rise in intestinal permeability compared to placebo, as measured by lactulose:rhamnose ratio. This is a small but well-designed pilot study; the finding is promising for athletes, though replication in larger trials is needed.

5. General gut lining support and "leaky gut"

The mechanistic properties of zinc carnosine — mucosal adhesion, zinc-mediated epithelial repair, carnosine antioxidant activity — have led to its inclusion in many "gut health" and "leaky gut" formulas. Clinical evidence for broad gut barrier improvement in non-specific populations (without gastric ulcer, H. pylori, NSAID use, or exercise stress) is largely absent. It should be viewed as a gastric-specific intervention, not a pan-gut-health supplement with broad proven utility.

Supplement forms compared

How much zinc carnosine should you take?

• Standard dose (matches research and Polaprezinc prescription): 75 mg of zinc-carnosine complex twice daily with meals = 150 mg/day total complex = approximately 34 mg elemental zinc per day
• Zinc RDA: 8 mg/day women; 11 mg/day men
• Zinc Tolerable Upper Limit (IOM): 40 mg/day from all sources combined (food + supplements)
• Implication: The standard PepZin GI dose provides 34 mg/day elemental zinc — only 6 mg below the UL. Individuals eating a zinc-rich diet (meat, shellfish, legumes) or taking any additional zinc-containing supplement must account for this. Exceeding the UL chronically is the main risk.
• Duration: Clinical trials have run for 8–12 weeks. Long-term use beyond 12 weeks should be monitored by a healthcare provider, particularly for copper status.
• If GI relief is the goal: Take 30–60 minutes before meals for best mucosal contact time, or follow the product label. Taking with meals is also acceptable and supported by clinical trial protocols.

Safety, side effects, and the zinc UL

Zinc carnosine has an excellent GI tolerability profile compared to other zinc supplements — partly because the intact chelate delays zinc release, reducing the immediate gastric irritation that makes zinc sulfate and even zinc gluconate nauseating for some users. Clinical trial dropout rates due to GI side effects have been low (<5%).

Common side effects (rare at standard doses)

• Mild nausea in some individuals — less frequent than with other zinc forms
• Metallic taste (dose-dependent)
• GI discomfort if taken on an empty stomach at higher doses

Copper deficiency risk — the main long-term concern

High zinc intake (above the 40 mg/day UL) chronically interferes with copper absorption by upregulating metallothionein in intestinal enterocytes, which binds copper preferentially and prevents its absorption. Symptoms of zinc-induced copper deficiency include microcytic anemia, neutropenia, and neurological symptoms. At the standard 150 mg/day PepZin GI dose (34 mg elemental zinc/day), the risk is low but meaningful — particularly if any other zinc is being consumed from diet or additional supplements. If using PepZin GI for more than 8 weeks, consider periodic monitoring of serum copper or ceruloplasmin, or take a small copper supplement (0.5–1 mg/day) to offset.

Kidney disease

Zinc is renally excreted. Individuals with advanced CKD should use zinc supplements (including zinc carnosine) only with nephrologist supervision to avoid accumulation.

Drug and nutrient interactions

• Antibiotics (quinolones, tetracyclines): Zinc chelates these antibiotics in the GI tract, reducing their absorption. Separate administration by 2+ hours. This is relevant when using PepZin GI as an H. pylori eradication adjunct — coordinate timing with your antibiotic regimen.
• Copper: High zinc suppresses copper absorption via metallothionein upregulation. If using long-term at full dose, monitor copper status or supplement 0.5–1 mg/day copper.
• Iron: Zinc and iron compete for the same intestinal absorption transporter (divalent metal transporter 1). High-dose zinc can reduce iron absorption. Separate iron supplements by 2+ hours.
• PPIs and H2 blockers: Often used concurrently in gastric ulcer management. No significant pharmacokinetic interaction; the combination is clinically common and acceptable.
• NSAIDs: If using PepZin GI specifically to protect against NSAID-induced mucosal damage, take PepZin GI with (or just before) the NSAID dose to maximize mucosal contact during peak NSAID gastric exposure.
• Cisplatin and other platinum-based chemotherapy: Zinc can reduce cisplatin-associated mucositis; this is an area of research but has not been studied with the carnosine form specifically.

Check our free interaction checker for additional combinations.

Who might benefit — and who shouldn't bother

Frequently asked questions

Quick facts

Related ingredients and articles